$3.32
−2.06%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.39
From 52W high−28.14%
Volume938195.00
Market cap$143.74M
P/E (TTM)—
P/S (TTM)42.4x
Div yield—
Key dataSep 18, 2026
Open
$3.39
From 52W high
−28.14%
Volume
938195.00
Market cap
$143.74M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.4x
P/E (TTM)
—
RSI (14)
45.9
MomentumView details →
1D Return
−2.06%
YTD Return
+24.54%
SummaryUpdated Jun 1, 2026
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Wilmington, Delaware. The company went public in December 2017 and focuses on developing novel therapeutics for central nervous system disorders, particularly targeting the treatment of suicidal depression and bipolar depression. NRx has evolved from a pure research and development organization into a company pursuing a dual strategy of drug development and clinical service delivery through its subsidiary Hope Therapeutics.
Similar companies
Latest newsMore news →
The FDA Office of Generic Drugs reclassified NRx Pharmaceuticals' amendment to its Abbreviated New Drug Application for preservative-free ketamine from a Major Amendment to a Minor Amendment.5d agoGeNeuro, Inc., an NRx company, was awarded European patent rights for GNK-301, a novel drug candidate for treating amyotrophic lateral sclerosis (ALS).6d agoNRx Pharmaceuticals completed the first-cycle FDA review of its ANDA for preservative-free ketamine with no drug-related major deficiencies, and submitted the sole remaining manufacturer's attestation on the vial to the FDA.34d ago